Literature DB >> 205674

Solubilization and characterization of Herpesvirus saimiri-induced membrane antigens.

L F Qaultiere, G R Pearson.   

Abstract

Treatment of Herpesvirus saimiri (HVS)-infected owl monkey cells by limited papain digestion removed the HVS-induced membrane antigen (MA) as determined by membrane immunofluorescence and antibody-dependent lymphocyte cytotoxicity (ADLC). Soluble antigenically active HVSMA was detected by inhibition of ADLC and by the decreased binding of 125I-labeled staphylococcus protein A to HVS-infected cells after absorption of an anti-MA-positive serum with papain extracts. Approximately 38% of the inhibitory activity of the papain extracts was sedimentable at 100,000 X g, indicating that the released MA was heterogeneous in size. Preliminary investigations by gel filtration chromatography identified a major peak of MA with a molecular weight between 20,000 and 50,000.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 205674      PMCID: PMC525979     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  20 in total

1.  ADSORPTION OF SENSITIZED SHEEP ERYTHROCYTES TO HELA CELLS INFECTED WITH HERPES SIMPLEX VIRUS.

Authors:  J F WATKINS
Journal:  Nature       Date:  1964-06-27       Impact factor: 49.962

2.  A solid-phase radioimmunoassay for Epstein-Barr virus-associated membrane antigen prepared from B95-8 cell culture supernatants.

Authors:  G Dölken; G Klein
Journal:  J Natl Cancer Inst       Date:  1977-05       Impact factor: 13.506

3.  Immune interactions with cells infected with herpes simplex virus: antibodies to radioiodinated surface antigens.

Authors:  J C Glorioso; J W Smith
Journal:  J Immunol       Date:  1977-01       Impact factor: 5.422

4.  Differentiation between early and late membrane antigen on human lymphoblastoid cell lines infected with Epstein-Barr virus. I. Immunofluorescence.

Authors:  I Ernberg; G Klein; F M Kourilsky; D Silvestre
Journal:  J Natl Cancer Inst       Date:  1974-07       Impact factor: 13.506

5.  Malignant lymphoma with lymphocytic leukemia induced in owl monkeys by Herpesvirus saimiri.

Authors:  D V Ablashi; W F Loeb; M G Valerio; R H Adamson; G R Armstrong; D G Bennett; U Heine
Journal:  J Natl Cancer Inst       Date:  1971-10       Impact factor: 13.506

6.  Proteins specified by herpes simplex virus. IX. Contiguity of host and viral proteins in the plasma membrane of infected cells.

Authors:  J W Heine; B Roizman
Journal:  J Virol       Date:  1973-05       Impact factor: 5.103

7.  Intracellular and membrane immunofluorescence investigations on cells infected with Herpesvirus saimiri.

Authors:  G Pearson; D Ablashi; T Orr; H Rabin; G Armstrong
Journal:  J Natl Cancer Inst       Date:  1972-11       Impact factor: 13.506

8.  Alterations of the immunological specificity of plasma membranes from cells infected with Marek's disease and turkey herpes viruses.

Authors:  O R Kaaden; B Dietzschold
Journal:  J Gen Virol       Date:  1974-10       Impact factor: 3.891

9.  Antibody reactions to herpesvirus saimiri (HVS)-induced early and late antigens (EA and LA) in HVS-infected squirrel, marmoset and owl monkeys.

Authors:  G Klein; G Pearson; A Rabson; D V Ablashi; L Falk; L Wolfe; F Dienhardt; H Rabin
Journal:  Int J Cancer       Date:  1973-07-15       Impact factor: 7.396

10.  Antibody responses to membrane antigens in monkeys infected with Herpesvirus saimiri.

Authors:  J M Prevost; G R Pearson; W C Wallen; H Rabin; L F Qualtiere
Journal:  Int J Cancer       Date:  1976-11-15       Impact factor: 7.396

View more
  2 in total

1.  Papain solubilization of the Epstein-Barr virus-induced membrane antigen.

Authors:  G R Pearson; L F Qualtiere
Journal:  J Virol       Date:  1978-10       Impact factor: 5.103

2.  In vitro cytotoxicity against Marek's disease lymphoblastoid cell lines after enzymatic removal of Marek's disease tumor-associated surface antigen.

Authors:  K A Schat; K K Murthy
Journal:  J Virol       Date:  1980-04       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.